The importance of HPV vaccination in men
Authors:
as. MUDr. Ph.D. Borek Sehnal; prof. MUDr. Ph.D. Roman Chlíbek; doc. MUDr. Ph.D. Jiří Sláma
Authors place of work:
Gynekologicko-porodnická klinika 1. LF UK a Nemocnice Na Bulovce: Budínova , 180 1 Praha
1; Fakulta vojenského zdravotnictví Univerzity obrany: Třebešská 1575, 500 01 Hradec Králové
2; Gynekologicko-porodnická klinika 1. LF UK a VFN v Praze: Apolinářská 18, 128 51 Praha
3
Published in the journal:
Čas. Lék. čes. 2016; 155: 200-205
Category:
Review Article
Summary
The important goal of immunization programs in many countries is the reduction of the incidence of cervical cancer using either the quadrivalent (Silgard/Gardasil) or the bivalent (Cervarix) HPV (human papillomavirus) vaccine. Nevertheless, HPV infection is associated with the development of cancers of anus, vagina, vulva and penis, and cancers of the head and neck and genital warts, too. Large trials for both vaccines find efficacy against HPV-related infection and different HPV associated diseases.
Infection with HPV and diseases caused by HPV are common in boys and men, too. Approximately 5.2 % of all cancers are HPV associated and the burden of HPV associated disease in men is now comparable to that in women in economically developed countries. Randomized control trials demonstrate robust antibody responses and high efficacy also in men. Several countries recommend gender-neutral vaccination.
Detailed cost effective modeling has preceded these decisions showing that when the burden of disease in men is included in the models then, depending upon vaccine price, coverage of a vaccinated population, and other factors male vaccination can become cost effective. Vaccine price had a decisive impact on results. However, increasing coverage in girls is substantially more effective and cost-effective than expanding vaccination coverage to boys and should be considered a priority. Since 2012, vaccination of girls at the age of 13-14 years has been covered from the health insurance in the Czech Republic.
Keywords:
human papillomavirus, HPV infection in men, HPV vaccination in men, anal cancer, penile cancer, head and neck squamous cell carcinomas, condylomata acuminata, cost effectiveness
Zdroje
1. Fehrmann F et al. Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation. Oncogene 2003; 22: 5201–5207.
2. Giuliano AR et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet 2011; 377(9769): 932–940.
3. Spitzer M. Human papillomavirus: epidemiology, natural history, and clinical sequelae. OBG Management 2006; 18: S5–S10.
4. Dunne EF et al. Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis 2006; 194: 1044–1057.
5. Hebnes JB et al. Prevalence of genital human papillomavirus among men in Europe: systematic review and meta-analysis. J Sex Med 2014; 11: 2630–2644.
6. Nyitray A et al. Prevalence of and risk factors for anal human papillomavirus infection in heterosexual men. J Infect Dis 2008; 197(12): 1676–1684.
7. Cranston RD et al. Anal human papillomavirus infection in a street-based sample of drug using HIV-positive men. Int J STD AIDS 2012; 23: 195–200.
8. Poynten IM et al. Prevalence, incidence, and risk factors for human papillomavirus 16 seropositivity in australian homosexual men. Sex Transm Dis 2012; 39: 726–732.
9. Machalek DA et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol 2012; 13: 487–500.
10. Goodman MT et al. Acquisition of anal human papillomavirus (HPV) infection in women: the Hawaii HPV Cohort study. J Infect Dis 2008; 197: 957–966.
11. Kreimer AR et al. Oral human papillomavirus in healthy individuals: a systematic review of the literature. Sex Transm Dis 2010; 37(6): 386–391.
12. Gillison ML et al. Prevalence of oral HPV infection in the United States, 2009–2010. JAMA 2012; 307(7): 693–703.
13. De Vuyst H et al. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009; 124: 1626–1636.
14. Parkin DM et al. The burden of HPV-related cancers. Vaccine 2006; 24: 11–25.
15. Driák D et al. Význam infekcí způsobených lidskými papilomaviry. Čas Lék Čes 2013; 152: 15–19.
16. Zandberg DP et al. The Role of Human Papillomavirus in Nongenital Cancers. CA Cancer J Clin 2013; 63: 57–81.
17. Walboomers JM et al.Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189(1): 12–19.
18. Edgren G et al. Risk of anogenital cancer after diagnosis of cervical intraepithelial neoplasia: a prospective population-based study. Lancet Oncol 2007; 8: 311–316.
19. Palefsky JM et al. Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis 2001; 183: 383–391.
20. Sehnal B et al. Spojitost anální a cervikální HPV infekce u rizikových žen. Prakt Gyn 2014; 18(1): 60–63.
21. Český národní webový portál epidemiologie nadorů. Systém pro vizualizaci onkologických dat. Institut biostatistiky a analýz Lékařské a Přirodovědecké fakulty Masarykovy univerzity (IBA MU). http://www.svod.cz
22. Backes DM et al. Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control 2009; 20: 449–457.
23. Hernandez BY et al. Human papillomavirus genotype prevalence in invasive penile cancers from a registry-based United States Front Oncol 2014; 4: 9.
24. Shabbir M et al. Primary prevention and vaccination for penile cancer. Ther Adv Urol 2013; 5(3): 161–169.
25. SPC Silgard. http://www.medicines.org.uk/emc/medicine/19016/SPC/gardasil/
26. Kreimer AR et al. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005; 14: 467–475.
27. Kašpírková J et al. Možnosti průkazu biologicky relevantní papilomavirové infekce u maligních nádorů hlavy a krku v diagnostické patologii. Cesk Patol 2013; 49: 29–34.
28. Herrero R. Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. J Infect Dis 2009; 199: 919–922.
29. Marty R et al. Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe. BMC Cancer 2013, 13: 10.
30. StanleyHPV vaccination in boys and men. Hum Vaccin Immunother 2014; 10: 2109–2111.
31. Zimet GD et al. HPV vaccine and males: Issues and challenges. Gynecol Oncol 2010; 117: S26–S31.
32. Edelstein ZR et al. Serum antibody response following genital α9 human papillomavirus infection in young men. J Infect Dis 2011; 204: 209–216.
33. Ali H et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013; 346: f2032.
34. Stupiansky NW et al. Human papillomavirus vaccine and men: what are the obstacles and challenges? Curr Opin Infect Dis 2012; 25(1): 86–91.
35. Burger EA et al. Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys. PLoS One 2014; 9(3): e89974.
36. Dobson SR et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013; 309(17): 1793–1802.
37. Baandrup L et al. Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis 2013; 40: 130–135.
38. Liddon N et al. Acceptability of human papillomavirus vaccine for males: a review of the literature. J Adolesc Health 2010; 46: 113–123.
39. Newman PA et al. HPV vaccine acceptability among men: a systematic review and meta-analysis. Sex Transm Infect 2013; 89: 568–574.
Štítky
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistČlánok vyšiel v časopise
Journal of Czech Physicians
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
Najčítanejšie v tomto čísle
- The importance of HPV vaccination in men
- Dermatomyositis
- Functional assessment of coronary stenosis by fractional flow reserve
- Matrix Gla protein as natural inhibitor of vascular calcification and potential treatment target